Villers-lès-Nancy, December 10, 2026, 6:00 p.m. CET – Equasens (ISIN: FR 0012882389 – Ticker: EQS), a leader in digital solutions for healthcare professionals, announces its financial calendar for the 2026 financial year. EventsDates2025 annual revenueFebruary 5, 2026 (after market close)2025 annual resultsMarch 30, 2026 (before market opens)2026 Q1 revenueApril 29, 2026 (after market close)Annual General MeetingJune 25, 20262026 Half-year revenueJuly 30, 2026 (after market clos ...

Core Points - Equasens Group announces the departure of Damien Valicon as Deputy Chief Executive Officer and Director of the Pharmagest Division, with François-Pierre Marquier appointed as his successor [2][3] - François-Pierre Marquier has been with Pharmagest since May 2021 and has held various leadership roles, including overseeing the Pharmacy France business since January 2023 [4] - The transition period for François-Pierre Marquier's appointment will be effective after approval from the Board of Directors [3] Company Overview - Equasens Group, founded over 35 years ago, is a leader in digital healthcare solutions, employing over 1,400 people across Europe [6] - The company specializes in business applications that support healthcare professionals in their daily operations, including electronic equipment, digital solutions, and healthcare robotics [7] - Equasens Group aims to improve coordination among healthcare professionals through interoperability solutions, enhancing patient care and system efficiency [8] Strategic Direction - The company follows a two-pronged development strategy that combines organic growth with targeted acquisitions at a European level [9] - Upcoming financial communications include Q2 2025 revenue on July 31, 2025, and H1 2025 results on September 26, 2025 [11]

Core Points - Equasens Group will hold its Annual Ordinary General Meeting on June 25, 2025, at 5:30 PM at its registered office in Villers-lès-Nancy [2] - The agenda and resolutions for the meeting were published in the French legal announcements on May 16, 2025 [3] - The Meeting Notice was published on June 6, 2025, detailing participation and voting procedures [4] Company Information - Equasens Group, founded over 35 years ago, is a leader in digital healthcare solutions, employing over 1,300 people across Europe [8] - The company provides specialized business applications that support healthcare professionals in various settings, including private practice and healthcare establishments [9] - Equasens Group focuses on interoperability solutions that enhance coordination among healthcare professionals, improving patient care and system efficiency [10] Meeting Logistics - The Annual General Meeting will be broadcast live online, with connection information available 48 hours prior to the meeting [7] - A replay of the meeting will also be accessible on the company's website for later viewing [7] - All relevant documents and voting forms are available on the company's website since June 4, 2025 [5]

Core Viewpoint - QHSLab Inc. is in advanced discussions for a strategic restructuring with Catheter Precision, Inc. to enhance financial flexibility and long-term growth outlook [1][7]. Financial Restructuring - The restructuring aims to significantly improve QHSLab's financial position by reducing near-term payment obligations, increasing the conversion price of existing debt instruments, and removing default-related overhang [2][8]. - The anticipated agreement will introduce a payment-in-kind (PIK) interest option and extend the maturity of the notes, allowing the company to redirect capital toward key growth initiatives [2][3]. Expected Benefits - The restructuring is expected to support growth and add value for shareholders, representing a major step toward long-term financial strength [3]. - The company plans to finalize the agreement and issue a formal announcement in the coming weeks [3]. Company Overview - QHSLab, Inc. provides digital healthcare solutions and point-of-care diagnostic tests to primary care physicians, utilizing advanced artificial intelligence algorithms for patient assessment and monitoring [5]. - The company's products are designed to improve patient monitoring and medical care while increasing revenues for physicians [5].